导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 3.40% | 1592/4773 |
| 近一周 | -1.82% | 1821/5462 |
| 近一月 | -3.49% | 2360/5421 |
| 近一季 | -5.31% | 2115/5209 |
| 近半年 | 2.91% | 998/4920 |
| 近一年 | 7.68% | 1430/4366 |
| 近两年 | 56.11% | 1344/2954 |
| 近三年 | 35.28% | 895/2253 |
| 成立以来 | 110.00% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-3.74% 3383/4961 |
15.77% 1631/5312 |
- - |
- - |
| 2025 | 19.31% 2228/4813 |
1.54% 1599/3635 |
1.07% 2476/4076 |
14.98% 2850/4524 |
1.11% 1522/4813 |
| 2024 | 19.05% 561/3463 |
2.59% 750/2808 |
-0.60% 794/3014 |
17.21% 1241/3129 |
-0.40% 1403/3463 |
| 2023 | -12.19% 1455/2656 |
2.33% 1376/2280 |
-5.72% 1523/2385 |
-1.98% 608/2515 |
-7.14% 2068/2655 |
| 2022 | -17.74% 625/2207 |
-12.33% 603/1919 |
8.24% 377/2016 |
-14.29% 1063/2113 |
1.15% 1367/2208 |
| 2021 | 2.47% 631/1822 |
-1.36% 478/1255 |
7.15% 697/1330 |
-4.86% 743/1466 |
1.90% 758/1822 |
| 2020 | 32.49% 482/1250 |
-8.27% 594/1028 |
16.29% 447/1067 |
11.01% 490/1164 |
11.89% 512/1184 |
| 2019 | 35.90% 365/1092 |
24.75% 494/754 |
0.15% 194/804 |
1.45% 398/850 |
7.22% 467/918 |
| 2018 | -21.10% 206/834 |
- - |
- - |
- - |
-11.19% 259/691 |
| 2017 | 20.62% 180/714 |
- - |
- - |
- - |
- - |
| 2016 | -3.98% 153/605 |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 华夏沪深300指数增强C VS. 长安沪深300非周期A(740101) |